Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473221 | 0.80 | NPC1 (0.61) | NPC1RAB9AROCK2CASP3PLAU | |
| SCHEMBL25581593 | 0.79 | NR3C1 (0.54) | PLAUPTPN1TRPV1ALDH1A1HPGD | |
| SCHEMBL926151 | 0.79 | PLAU (0.56) | NPC1RAB9ACASP3PLAUMAOB | |
| SCHEMBL5414315 | 0.77 | KEAP1 (0.58) | RAB9ACASP3POLBALDH1A1ENPP2 | |
| SCHEMBL27698981 | 0.77 | KEAP1 (0.56) | NPC1RAB9APTPN1POLBTRPV1 | |
| SCHEMBL17420472 | 0.76 | NPC1 (0.68) | NPC1RAB9ACASP3PLAUMAOB | |
| SCHEMBL3786444 | 0.76 | NPC1 (0.68) | NPC1RAB9ACASP3PLAUMAOB | |
| Bicarbonate SCHEMBL5821894 | 0.75 | NPC1 (0.56) | NPC1RAB9AROCK2CASP3PLAU | |
| SCHEMBL30026274 | 0.75 | PDPK1 (0.57) | PTPN1TRPV1ALDH1A1KEAP1 | |
| SCHEMBL5497010 | 0.75 | PDPK1 (0.57) | PTPN1TRPV1ALDH1A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723105-B1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | LILLY CO ELI (US) | 2013-05-15 | — | — | EP | disclosed |
| US-7728150-B2 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728150-B2 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728150-B2 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-08-09 | — | — | US | disclosed |
| EP-1723105-A1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005092854-A1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092854-A1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR1H2 | NPC1 371/4885RAB9A 4619/4885ROCK2 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.